Anlotinib plus chemotherapy as first-line therapy for gastrointestinal tumor patients with unresectable liver metastasis: Updated results from a multi-cohort, multicenter phase II trial ALTER-G-001-cohort C

被引：0
|
作者：
Wu, J. [1 ]
Zhou, C. [1 ]
Yan, J. [2 ]
Han, Z. [3 ]
Wang, C. [2 ,5 ]
Qin, Z. [4 ]
Jiang, J. [1 ]
Wang, C. [2 ,5 ]
Tang, X. [6 ]
Zhu, L. [7 ]
Chen, J. [8 ]
Mao, Y. [9 ]
Wei, X. [10 ]
Shangguan, C. [1 ]
Zhang, J. [1 ]
机构：
[1] Shanghai Jiao Tong Univ, Ruijin Hosp, Dept Oncol, Sch Med, Shanghai, Peoples R China
[2] Jiading Cent Hosp, Dept Oncol, Shanghai, Peoples R China
[3] Xuzhou Med Univ, Affiliated Hosp, Dept Oncol, Xuzhou, Jiangsu, Peoples R China
[4] Zhejiang Prov Peoples Hosp, Dept Oncol, Hangzhou, Peoples R China
[5] 3 Peoples Hosp Yancheng, Dept Oncol, Yancheng, Peoples R China
[6] Ruijin Hosp, Wuxi Branch, Dept Oncol, Wuxi, Jiangsu, Peoples R China
[7] Nanjing Med Univ, Affiliated Hosp 1, Jiangsu Prov Hosp, Dept Oncol, Nanjing, Peoples R China
[8] Ningbo Univ, Affiliated Peoples Hosp, Dept Oncol, Ningbo, Peoples R China
[9] Jiangnan Univ, Wuxi Peoples Hosp 4, Dept Oncol, Wuxi, Jiangsu, Peoples R China
[10] Nanjing First Hosp, Dept Oncol, Nanjing, Peoples R China
来源：
ANNALS OF ONCOLOGY | 2023年 / 34卷
关键词：
D O I：
10.1016/j.annonc.2023.10.285
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
150P
引用
收藏
页码：S1533 / S1533
页数：1
相关论文
共 50 条
  • [31] First-line osemitamab (TST001) plus nivolumab and capox for advanced g/GEJ cancer (TranStar102): Results of cohort G from a phase I/IIa study
    Zhang, Xiaotian
    Guo, Zengqing
    Zhang, Jingdong
    Guo, Weijian
    Sun, Meili
    Xu, Nong
    Qi, Charlie
    Zhu, Xuelian
    Zhang, Lijuan
    Qian, Xueming
    Germa, Caroline
    Shen, Lin
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [32] Anlotinib combined with CAPEOX in first-line treatment of patients with RAS and BRAF wild-type unresectable metastatic colorectal cancer: A single-arm, phase II study (ALTER-C-002 trial).
    Ding Ke-Feng
    Liu Yue
    Chen Jiaqi
    Sun Lifeng
    Xu Dong
    Liao Xiujun
    Xiao Qian
    Li Jun
    Yuan Ying
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (03)
  • [33] Cetuximab plus mFOLFOX-6 as first-line therapy for unresectable liver metastases from colorectal cancer: an open-label, non-randomized, multicenter phase II clinical trial (CLIME Study)
    Cai, S.
    Zhang, W. E. N.
    Li, W.
    Xu, Y.
    Gu, W.
    Guan, Z.
    Cai, J. Q.
    Song, C.
    Xu, J. M.
    Chi, P.
    EUROPEAN JOURNAL OF CANCER, 2013, 49 : S541 - S541
  • [34] Second-line nintedanib plus docetaxel for patients with lung adenocarcinoma after first-line chemo-immunotherapy treatment: updated efficacy and safety results from VARGADO Cohort C
    Grohe, C.
    Wehler, T.
    Dechow, T.
    Henschke, S.
    Schuette, W.
    Dittrich, I
    Hammerschmidt, S.
    Mueller-Huesmann, H.
    Schumann, C.
    Krueger, S.
    Atz, J.
    Kaiser, R.
    ONCOLOGY RESEARCH AND TREATMENT, 2021, 44 : 110 - 110
  • [35] Second-line nintedanib plus docetaxel for patients with lung adenocarcinoma after first-line chemo-immunotherapy treatment: Updated efficacy and safety results from VARGADO Cohort C
    Grohe, C.
    Wehler, T.
    Dechow, T.
    Henschke, S.
    Schuette, W.
    Dittrich, I.
    Hammerschmidt, S.
    Mueller-Huesmann, H.
    Schumann, C.
    Krueger, S.
    Atz, J.
    Kaiser, R.
    ANNALS OF ONCOLOGY, 2021, 32 : S1018 - S1019
  • [36] Safety and efficacy of anlotinib plus docetaxel in advanced non-small cell lung cancer patients after failure of first-line chemotherapy: Recent results from the ongoing phase II study (ALTER-L024)
    Jin, B.
    Wang, G.
    Zhang, Y. L.
    Wu, R.
    Chen, J.
    Dong, Y.
    Peng, L. Y.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (04) : S793 - S793
  • [37] Combination of rituximab, bortezomib, doxorubicin, dexamethasone and chlorambucil (RiPAD plus C) as first-line therapy for elderly mantle cell lymphoma patients: results of a phase II trial from the GOELAMS
    Houot, R.
    Le Gouill, S.
    Uribe, M. Ojeda
    Mounier, C.
    Courby, S.
    Dartigeas, C.
    Bouabdallah, K.
    Vigier, M. Alexis
    Moles, M. P.
    Tournilhac, O.
    Arakelyan, N.
    Rodon, P.
    El Yamani, A.
    Sutton, L.
    Fornecker, L.
    Assouline, D.
    Harousseau, J. L.
    Maisonneuve, H.
    Caulet-Maugendre, S.
    Gressin, R.
    ANNALS OF ONCOLOGY, 2012, 23 (06) : 1555 - 1561
  • [38] Efficacy and safety of anlotinib combined with CAPEOX in first-line treatment of patients with RAS and BRAF wild-type unresectable metastatic colorectal cancer - A single-arm, multi-center, phase II study (ALTER-C-002 trial)
    Ding, K.
    Liu, Y.
    Chen, J.
    Ying, J.
    Xu, Q.
    Xu, D.
    Sun, L.
    Yuan, Y.
    ANNALS OF ONCOLOGY, 2020, 31 : S440 - S440
  • [39] Updated results from KEYNOTE-021 cohort G: A randomized, phase 2 study of pemetrexed and carboplatin (PC) with or without pembrolizumab (pembro) as first-line therapy for advanced nonsquamous NSCLC
    Borghaei, H.
    Langer, C. J.
    Gadgeel, S.
    Papadimitrakopoulou, V. A.
    Patnaik, A.
    Powell, S. F.
    Gentzler, R. D.
    Martins, R. G.
    Stevenson, J. P.
    Jalal, S. I.
    Panwalkar, A.
    Yang, J. C-H.
    Gubens, M.
    Sequist, L.
    Awad, M. M.
    Fiore, J.
    Saraf, S.
    Raftopoulos, H.
    Gandhi, L.
    ANNALS OF ONCOLOGY, 2017, 28
  • [40] OUTCOMES OF FIRST-LINE PALLIATIVE SYSTEMIC THERAPY ALTERNATED WITH OXALIPLATIN-BASED PRESSURIZED INTRAPERITONEAL AEROSOL CHEMOTHERAPY IN PATIENTS WITH UNRESECTABLE COLORECTAL PERITONEAL METASTASES IN A MULTICENTER, SINGLE-ARM, PHASE II TRIAL
    van de Vlasakker, Vincent C.
    Rauwerdink, Paulien
    Rovers, Koen P.
    Wassenaar, Emma
    Deenen, Maarten J.
    Nederend, Joost
    Huysentruyt, Clement
    Fijneman, Remond J.
    van der Hoeven, Erik
    Raicu, G.
    Constantinidis, Alexander
    Kranenburg, Onno
    Los, Maartje
    Creemers, Geert-Jan
    Burger, Jacobus
    Wiezer, Marinus
    Nienhuijs, Simon
    Lurvink, Robin
    Boerma, Djamila
    de Hingh, Ignace H.
    GASTROENTEROLOGY, 2023, 164 (06) : S1489 - S1489
12345